Sumitomo Pharma Co., Ltd. (DNPUF)
OTCMKTS
· Delayed Price · Currency is USD
8.97
0.00 (0.00%)
At close: Aug 13, 2025
Sumitomo Pharma Revenue
Sumitomo Pharma had revenue of 108.00B JPY in the quarter ending June 30, 2025, with 19.11% growth. This brings the company's revenue in the last twelve months to 416.16B, up 26.28% year-over-year. In the fiscal year ending March 31, 2025, Sumitomo Pharma had annual revenue of 398.83B with 26.79% growth.
Revenue (ttm)
416.16B JPY
Revenue Growth
+26.28%
P/S Ratio
1.29
Revenue / Employee
108.60M JPY
Employees
3,832
Market Cap
3.73B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 398.83B | 84.27B | 26.79% |
Mar 31, 2024 | 314.56B | -240.99B | -43.38% |
Mar 31, 2023 | 555.54B | -4.49B | -0.80% |
Mar 31, 2022 | 560.04B | 44.08B | 8.54% |
Mar 31, 2021 | 515.95B | 33.22B | 6.88% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 206.83M |
Elite Pharmaceuticals | 84.04M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
BioStem Technologies | 332.45M |